Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch & LombBLCO +0.12%76 12-1 Month Momentum % is 14.16% as of Aug. 30, 2026. GuruFocus rates BLCO with a GF Score™ of 76/100 and a GF Value™ of $17.95 (Fairly Valued). The stock has 7 warning signs investors should review. Among 828 Medical Devices & Instruments companies, Bausch & Lomb ranks better than 83.82% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-30), Bausch & Lomb's 12-1 Month Momentum % is 14.16%.
The industry rank for Bausch & Lomb's 12-1 Month Momentum % or its related term are showing as below:
BLCO's 12-1 Month Momentum % is ranked better than 83.82% of 828
companies
in the Medical Devices & Instruments industry
Industry Median: -19.56
vs BLCO: 14.16
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Bausch & Lomb 12-1 Month Momentum % Related Terms
BLCO vs ISRG, BDX, MDLN: 12-1 Month Momentum % Comparison
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb 12-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (BLCO) has a 12-1 Month Momentum % of 14.16% as of Aug. 30, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Bausch & Lomb and its competitors. According to the industry distribution chart, Bausch & Lomb ranks #134 out of 828 companies in the Medical Devices & Instruments industry, placing it in the top 16.2%.
Is Bausch & Lomb's 12-1 Month Momentum % too high?
Bausch & Lomb's current 12-1 Month Momentum % is 14.16%. Based on the distribution chart, Bausch & Lomb ranks #134 out of 828 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bausch & Lomb has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's 12-1 Month Momentum % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #134 out of 828 companies for 12-1 Month Momentum %. This places Bausch & Lomb in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Devices & Instruments company?
A good 12-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Bausch & Lomb and its competitors. Bausch & Lomb's current 12-1 Month Momentum % is 14.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Fairly Valued. The stock's GF Value™ is $17.95, compared to a current price of $17.15 — trading 4.5% below its estimated fair value. The current 12-1 Month Momentum % is 14.16%. Bausch & Lomb's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current 12-1 Month Momentum % is 14.16% as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of $17.15 is trading 4.5% below its estimated GF Value™ of $17.95.
GuruFocus considers Bausch & Lomb to be Fairly Valued.
Key valuation signals for BLCO:
12-1 Month Momentum %: 14.16%
GF Value™: $17.95 vs. price of $17.15 (4.5% below fair value)
No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
76GF Score
Get the complete analysis for BLCO
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLCO has been successfully added to your 
